These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32445125)

  • 21. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
    Terauchi Y; Usami M; Inoue T
    Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
    Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
    Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: The Impact GLP-1 CKD study.
    Chu L; Bradley RM; Auerbach P; Abitbol A
    Diabetes Obes Metab; 2024 Oct; 26(10):4674-4683. PubMed ID: 39113258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
    Jung H; Tittel SR; Schloot NC; Heitmann E; Otto T; Lebrec J; Pavel M; Lanzinger S
    Diabetes Obes Metab; 2023 Jul; 25(7):1813-1822. PubMed ID: 36855221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone.
    Wright EE; Roberts GJ; Chuang JS; Nabutovsky Y; Virdi N; Miller E
    Diabetes Technol Ther; 2024 Oct; 26(10):754-762. PubMed ID: 38669474
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53).
    Maegawa H; Ishigaki Y; Langer J; Saotome-Nakamura A; Andersen M;
    J Diabetes Investig; 2021 Mar; 12(3):374-381. PubMed ID: 32643314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study.
    Tramunt B; Disse E; Chevalier N; Bordier L; Cazals L; Dupuy O; Marre M; Matar O; Meyer L; Noilhan C; Sanz C; Valensi P; Velayoudom FL; Gautier JF; Gourdy P
    Diabetes Ther; 2022 Dec; 13(11-12):1947-1963. PubMed ID: 36331712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors and Clinical Outcomes of Treatment Intensification in Patients With Type 2 Diabetes Uncontrolled on Basal Insulin in a Real-World Setting.
    Kallenbach L; Shui AM; Cheng WY; Fan T; Hu W; Zichlin ML; Duh MS; Ye F; Levin PA
    Endocr Pract; 2018 Sep; 24(9):805-814. PubMed ID: 29975575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
    Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
    J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.
    Bailey TS; Gill J; Jones S M; Shenoy L; Nicholls C; Westerbacka J
    Diabetes Obes Metab; 2022 Aug; 24(8):1617-1622. PubMed ID: 35491520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
    Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
    J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
    [No Abstract]   [Full Text] [Related]  

  • 35. Third-Line Antidiabetic Therapy Intensification Patterns and Glycaemic Control in Patients with Type 2 Diabetes in the USA: A Real-World Study.
    Koye DN; Montvida O; Paul SK
    Drugs; 2020 Apr; 80(5):477-487. PubMed ID: 32141024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA; Baron MA; Gao L; Blonde L
    Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin.
    Chou HW; Cheng KP; Lin AC; Hung HC; Lin CH; Wang CC; Wu HT; Ou HY
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.
    Lee SM; Aboubechara N; Niu F; Ledesma VM; Patel YA; Millares M; Hui RL
    J Manag Care Spec Pharm; 2019 Mar; 25(3):350-356. PubMed ID: 30816819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA.
    Singhal M; Tan H; Coleman CI; Han M; Nguyen C; Ingham M
    BMJ Open Diabetes Res Care; 2019; 7(1):e000704. PubMed ID: 31798890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
    Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
    Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.